Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

What was studied

This analysis looked at how the drug depemokimab moves through the body and acts. It used data from early-stage and late-stage studies. The people had asthma or chronic rhinosinusitis with nasal polyps. The team built models for drug levels and for the blood eosinophil count. The count is a marker of type 2 inflammation. Drug levels came from 961 people. The marker model came from 1324 people.

What they found

Little build-up of the drug occurred. A 100 mg dose cut eosinophil counts quickly. A small rise came at the end of the 26-week dosing gap. All people had drug levels above the EC50 at the end of the gap. No clinically relevant covariates were found.

What it means for patients

The authors say one 100 mg dose cut eosinophil counts across a 26-week gap. They say this suggests lasting suppression of IL-5 activity. They say the data back dosing every 26 weeks. They found no need to adjust the dose for personal or outside factors.

Why it is not certain yet

This is a modelling analysis of drug levels and a blood marker. It does not report symptoms. The levels are predictions from models. The models rest on the studies they used.

Source

Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps.

We restate facts from the source record in our own words. The original wording belongs to its publisher.